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Introduction
Cancer patients in all parts of the world are high users of herbal medicines (HMs), which they choose for clinical reasons related to their cancer diagnosis (Poonthananiwatkul 2015) and which they usually take as part of a regime consisting of several complementary and alternative medicine (CAM) modalities (Alsanad et al 2014; McLay et al 2012) . The contribution of HMs cannot easily be separated from those of other forms of CAM, although they are more likely to possess pharmacological effects and/or interact with conventional medicines. The specific reasons why patients take HM-CAM regimes have not been completely identified but include trying to actively treat cancer, reduce symptoms of the disease, ameliorate side effects associated with conventional treatments, prevent further recurrence or metastasis of the cancer, and to enhance general health in order to deal with the disease and its treatment (Poonthananiwatkul 2015; Alsanad et al 2014; Ernst 2009 ). A recent study of cancer patients at a traditional medicine hospice in Thailand suggested that in general herbal medicines were perceived to provide more benefit than harm, and a preliminary assessment of the herbal regime, using changes in symptom burden after staying at the hospice, supported this (Poonthananiwatkul 2015) . HMs can be registered as medicines in the European Union, but not in most other countries, and 'nutritional' products are poorly regulated everywhere. HMs are often sold as 'food' or 'dietary' supplements to circumvent the regulations; however, as they are taken for therapeutic purposes they are considered to be HMs for the purposes of this study. The first step to addressing the problem of uncontrolled use of HMs as self-medication is therefore to explore the reasons why patients feel the need to take them. Perceptions of the efficacy and safety of these medicines influence the products chosen, although patients are unlikely to consider the indirect consequences of taking these medicines, including their interaction with conventional medicines or other supplements (Goey et al 2014; Zeller et al 2013) . The issues posed by combining herbal medicines with conventional drugs have been well documented over the last decade (e.g. Alsanad et al 2014; McLay et al 2012; Williamson et al 2013) and patients in many countries are now being advised to avoid taking herbal medicines during conventional cancer treatment, although no published evidence is available to confirm this as a policy. The objective of this review is to summarize the socio-demographic and other factors that influence HM-CAM use in cancer patients, and their perceptions towards their benefit or harm.
Materials and methods

Search strategy
Data collected in ethnobotanical research has well-documented weaknesses, as critically reviewed by Heinrich et al (2009) , and one of these is that datasets compiled regionally in local languages may not be available internationally. In order to investigate whether any such 'hidden studies' were available, two separate reviews were carried out: the first, a search of Science Citation Indexed, peer-reviewed journals in Medline; the second, a search of the national databases in Thailand. The purpose of the Thai review was to act as an example to investigate whether extra information could be gained by casting the net more widely, despite the unreliability of non-peer-reviewed sources. The Thai databases were used as a test case because Thailand is a very high user of herbal medicines, they are comprehensive and we had access to the full dataset. The searches were restricted to 2003 onwards to provide a contemporary context and also because as a preliminary search found very few relevant studies prior to this. Even peer-review cannot guarantee quality so as many details as possible about each study (method, sample size, other findings) are The off-line Khampramong research database was also searched using the same terms, as an example of an institutional data resources. All English language studies published between 2003 and 2014 identifying the experiences/ attitudes/ perceptions/ intended purposes of cancer patients regarding HM were included. Review articles, operational (e.g. clinical guidelines) and health services (e.g. cancer screening) research, case reports, studies on CAM which did not include HM use or surveys of other parties (such as physicians and other healthcare providers), and laboratory and animal studies were excluded. Studies looking purely at prevalence, trends and costs of herbal medicines were also omitted, as were studies on herb-drug combinations or side effects.
Data extraction
Full papers were obtained for studies considered relevant (figs 1 and 2) and read through by BP. To ensure validity, they were checked by Dr Saud Alsanad (College of Medicine, Al-Imam Mohammad Bin Saud Islamic University, Riyadh, KSA). The following data were extracted from the selected papers: author, year of publication, country, method used, response rate (%), sample size or calculation reported, cancer type, factors related to use of herbal medicine, purposes and thematic concepts cited for use. Factors such as age, gender, education level, income, type of cancer, previous conventional treatment and HM use were recorded, and also sources of information, which may influence decisions to use these products. Perceptions of benefit or harm resulting from taking these products were evaluated, but it must be emphasised that these are the opinions of patients who voluntarily took part in the studies cited, and are reported without any corroboration by independent assessment, clinical examination or biochemical tests. This is an intrinsic but unavoidable weakness of such studies.
5,638 records were found in the Medline database, but only 170 were judged relevant based on the title, i.e. they specifically examined herbal medicine use in cancer patients. 49 papers were eventually included in the review, as shown in figure 1. The Thai database search initially found 155 records, and 14 studies of herbal medicine use in cancer patients were selected based on the title (Fig 2) . Titles and abstracts were read through by author BP and validated by a Thai speaker, Dr Supaporn Bunsiriluck (Sirindhorn College of Public Health, Thailand). No Thai language studies were found which fulfilled the criteria for inclusion, so no further analysis was undertaken for these studies. Studies not relevant based on the title of the study (Excluded studies were case reports, health service laboratory studies, animal studies, those involving
Citations identified from all Thai databases (n=155)
Purposes cited by cancer patients for taking herbal medicines as part of a CAM regime The main reasons given by cancer patients as to why they use HM-CAM are illustrated in fig 3; which in fact shows that this type of analysis is not particularly useful, as there is so much overlap in potential meaning in the reasons cited by the patients themselves. We used the terms cited in the studies to try to avoid misinterpretation, but these are highly subjective. Not all studies used the same parameters, terminologies and methodologies, and more than one purpose was frequently cited by patients who also often used multiple types of CAM. Although all the studies reviewed included HM as a category of CAM, most could not differentiate findings from each modality, so it is not possible to ascribe all the findings to HM use. A further complication is that the line between HM and dietary supplements is not clear, and can depend on non-clinical issues such as legal classification.
CAM and HM in particular are to alleviate physical symptoms associated with cancer, but this category could easily include 'improving general health and the ability to fight the disease', as well as 'treating cancer' and 'improving quality of life', although these reasons were also described specifically. Similarly, 'supporting emotional or mental health' could include 'taking an active role in treatment', 'managing stress' and 'feeling in control'.
'Stimulating or boosting the immune system' was also considered very important, and whereas few studies reported that using HM was intended to achieve a longer life-span, this is implicit in most other categories such as preventing recurrence and treating or curing cancer. Only one study one suggested that 'dissatisfaction with conventional medicine', but the fact that so many cancer patients use HM-CAM suggests that they do not think that conventional medicine has all the answers. Fig 3 therefore also illustrates the importance of using standardised terminology or the use of thematic coding, rather than relying on patients' own descriptions verbatim for this kind of study. Despite this, almost all of the categories relate to the desire to be actively involved in treatment, and the impetus to use HM-CAM comes from patients, rather than practitioners. 
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Orthopaedic Enhance physical well-being and improve wound-healing.
Influence of family and friends. 66% 'benefitted' from CAM; 5 patients reported side effects. ~30% discussed with physician.
46 Huebner et al. The more serious disease states were associated with CAM which included HM and dietary supplements (HM-CAM). Multiple chemotherapy treatment was related to higher HM-CAM usage and many patients started using CAM (of any type) only after being diagnosed with cancer. However, those who had used HM-CAM for other purposes were also more likely to be associated with its use in cancer. A greater use of HM-CAM was noted in cancer patients who were in a recurrent or metastatic stage (e.g. Cui et al., 2004) and the longer the time since the initial cancer diagnosis, the more likely patients were to use HMs (Salminen et al., 2004) . These reasons may be related to other factors such as 'fearfulness about the future'
and 'anxiety about possible recurrence', which were also linked with a greater tendency to use HM-CAM (Correa-Velez et al., 2003 , Bismark et al., 2014 .
Experiences reported by patients after taking herbal medicines
The recorded incidence of herbal use varies widely, i.e. between 10.8% and 90.2%, but all the studies reviewed showed that at least 55% of patients believed they had had benefited, whereas few patients (8% to 18%) reported negative effects (Damery et al., 2011 , Nazik et al., 2012 , Molassiotis et al., 2006 , Chen et al., 2008 , Tuna et al., 2013 , Bonacchi et al., 2014 .
Perceived beneficial experiences: Previous studies have reported positive effects after HM-CAM use but results varied greatly. Between 22% and 90% of patients said they had experienced benefits, the most common being relief of pain, dyspepsia and fever, and improved appetite and patterns of sleep (Oh et al., 2010 , Molassiotis et al., 2005 , Puataweepong et al., 2012 , Hyodo et al., 2005 , Teng et al., 2010 , Ladas et al., 2014 , Trevena and Reeder, 2005 . Other perceived benefits were a greater ability to cope with the illness and its treatment or specific effects in relieving pain and adverse effects of conventional medicine including chemotherapy (i.e. nausea), as well as alleviating severe depression or anxiety and improving emotional health, as shown in table 1.
Perceived negative experiences reported by patients after taking HMs: Negative effects from HM-CAM reported by cancer patients ranged from 3% to 9.4% and included pain, dyspepsia, abdominal pain and fatigue (Oh et al., 2010 , Molassiotis et al., 2005 , Puataweepong et al., 2012 , Hyodo et al., 2005 , Trevena and Reeder, 2005 . As with perceived benefit, it is not possible to ascribe all of these to the HM-CAM treatment and some may be due to progression of the disease.
Other findings of the review Concurrent use with conventional therapies: most studies found that over 50% of patients who used HM-CAM did so along with conventional medicines (e.g. Nazik et al., 2012 , Gupta et al., 2005 , Helyer et al., 2006 , many to treat specifically the adverse effects of conventional treatment (e.g. Gupta et al., 2005 , McLay JS et al., 2012 .
Informing medical practitioners of HM use: differences were noted between countries but the number of studies cited was insufficient to draw any conclusions. Most strikingly, two US and two UK studies reported that the majority of patients surveyed did not tell their doctor of their HM-CAM use, whereas in two Australian studies, the majority either informed or intended to inform their doctor. In Turkey, Italy, Israel and Germany (1 study each), most patients discussed their HM-CAM use with their GP, but in Thailand, most did not (1 study).
Discussion
Many studies have investigated the use of CAM generally in cancer patients, which is commonplace (e.g. Teng et al 2010) , and in some cases this has included HM (including dietary supplements). HM is the main form of CAM which can interact with conventional drugs, so the implications of HM use are more serious (e.g. Alsanad et al 2014) and therefore formed the focus of this investigation. As most users of CAM use more than one modality, we have examined all studies which specified the HM as part of their regime. Although in traditional Chinese medicine (TCM) for example, combining conventional with herbal medicine in cancer treatment is endorsed by physicians and may be beneficial (e.g. Hu et al 2015; Cui et al 2004) , patients usually used HM-CAM on their own initiative and without informing their doctor, and many considered it was not necessary to do so.
The most common reasons for taking HM-CAM found in this study were linked to the desire to improve physical and mental symptoms and quality of life, and to help deal with the disease and its unpleasant treatment. As CAM is not sanctioned officially by most medical authorities, and not usually covered by public insurance schemes, it requires independent research into self-care health options, for example by using the internet and media. This may be a reflection of the findings that younger patients and those of a higher educational and financial status were associated with a higher use of HM-CAM.
This study also showed that most of the relevant information on HM-CAM is available in the mainstream, peer-reviewed literature. A comprehensive set of Thai databases compiled from local studies was used as an example for exploration; however, it provided no new information and did not even identify two Thai clinical studies published internationally (Piamjariyakul et al 2010; Puataweepong et al. 2012) . This is understandable since authors prefer to publish in SCI journals, although the results cannot be extrapolated elsewhere until further studies have been done.
Conclusions
This review identified several indicators for cancer patients who are most likely to take HM-CAM, using information taken from Medline. Fears that the results of local studies published regionally are being missed, at least in the case of Thailand, appeared to be unfounded. In addition to patient characteristics as described above, the use of HM-CAM was also associated with the type and stage of cancer and the side-effects of conventional treatment experienced. However, interpreting the specific clinical purposes why patients decide to use HM-CAM, and what they expected of and experienced from the treatments, is hampered by a lack of standard terminology and thematic coding. Patients' own descriptions are too variable and overlapping for meaningful comparison, but even so, most the categories relate to a desire to be actively involved in treatment, to improve general health and aid recovery. The impetus to use HM-CAM comes mainly from patients, rather than practitioners, except in China where integration of TCM and conventional medicine for cancer treatment is more common.
